SCHEMBL2605064

SCHEMBL2605064

O=C(NC1c2ccccc2-c2c(-c3cn[nH]c3)cccc21)c1ccnc2[nH]ccc12

nearest known ligand 0.65

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 5/20 0.65
AURKA O14965 1/20 0.49
AURKB Q96GD4 1/20 0.49
INCENP Q9NQS7 1/20 0.49
TPX2 Q9ULW0 1/20 0.49
AKT1 P31749 1/20 0.44
JAK1 P23458 9/20 0.40
NUDT1 P36639 2/20 0.39
TNKS O95271 1/20 0.38
JAK2 O60674 3/20 0.38
ADRA1D P25100 1/20 0.37
ADRA1A P35348 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2605037 0.87 HSP90AB1 (0.63) HSP90AB1AURKAAURKBINCENPTPX2
SCHEMBL2605069 0.87 HSP90AB1 (0.62) HSP90AB1AURKBAKT1JAK1NUDT1
SCHEMBL2077847 0.87 HSP90AB1 (0.69) HSP90AB1AURKBAKT1JAK1NUDT1
SCHEMBL2605027 0.87 HSP90AB1 (0.71) HSP90AB1AURKBAKT1JAK1NUDT1
SCHEMBL2605106 0.86 HSP90AB1 (0.66) HSP90AB1AURKAAURKBJAK1NUDT1
SCHEMBL2605099 0.86 HSP90AB1 (0.66) HSP90AB1AURKBAKT1JAK1NUDT1
SCHEMBL2605031 0.85 HSP90AB1 (0.63) HSP90AB1NUDT1TNKSJAK2
SCHEMBL3556400 0.85 HSP90AB1 (0.67) HSP90AB1AURKBJAK1NUDT1TNKS
SCHEMBL3556397 0.85 HSP90AB1 (0.67) HSP90AB1AURKBJAK1NUDT1TNKS
SCHEMBL3556403 0.85 HSP90AB1 (0.67) HSP90AB1AURKBJAK1NUDT1TNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163750-B2 Fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone HSP 90 SANOFI-AVENTIS (FR) 2012-04-24 US disclosed
US-8163750-B2 Fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone HSP 90 SANOFI-AVENTIS (FR) 2012-04-24 US disclosed
US-20100130503-A1 NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 SANOFI-AVENTIS (FR) 2010-05-27 US disclosed
US-20100130503-A1 NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 SANOFI-AVENTIS (FR) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130503-A1 NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 HSP90AB2P, HSPA2, HSP90AB1 HSP90AB1 3/4885AURKA 4237/4885AURKB 4063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.